Company

nChroma Bio, Inc.

nChroma Bio develops genetic medicines using epigenetic editing and in vivo delivery technologies.

About

Based in the US, nChroma Bio develops targeted genetic medicines, including CRMA-1001 for chronic hepatitis B and D. Its work includes gene regulation and non-viral delivery technologies. Formed through the merger of Chroma Medicine and Nvelop Therapeutics, the company raised USD 75 million in venture funding in December 2024, co-led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners, with participation from 5 AM Ventures, Data Collective, F-Prime Capital, GV, Janus Henderson Investors, Mubadala Capital, Omega Funds, Sixth Street, Sofinnova Partners, and others.

1Funding rounds

16Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in